NeuroVox Analytics Ltd., a Glasgow medtech startup, closed a £1.1 million pre-seed round led by Eos Advisory with Scottish Enterprise matching funds, according to filings at Companies House and term sheets reviewed by InfoHandle. The company will pilot voice-biomarker stroke triage software at Scottish Ambulance Service hub sites before paramedics transport suspected large-vessel occlusion patients to neuro-interventional centres.

What the round bought

Pre-seed proceeds cover clinical study staff, GPU inference servers hosted in a UK South data centre, and integration with hub dispatch tablets already running trauma protocols. Founders diluted to 68 percent combined; Eos took 18 percent with standard pre-emption rights; an NHS Greater Glasgow and Clyde clinical advisory vehicle holds 4 percent non-voting shares in exchange for consultant time.

The cap table includes an option pool sized for two machine-learning engineers recruited from Strathclyde University’s biomedical acoustics lab.

What the product claims—and what is unverified

NeuroVox says thirty-second speech samples collected during hub nurse callbacks can flag slurred phonemes and prosody shifts associated with acute stroke. Internal retrospective tests on archived call audio reportedly hit 0.81 sensitivity on confirmed infarcts, but independent peer review has not been published. MHRA has not classified the software as a medical device yet; the company filed a borderline enquiry in August.

Scottish Ambulance Service emphasised the pilot is observational: paramedics will not change transport decisions based on NeuroVox scores until a separate clinical investigation device exemption pathway clears.

Why ambulance hubs, not A&E

Hub-and-spoke models consolidated stroke bypass decisions at three west-of-Scotland sites where consultants read CT angiography remotely. Voice triage aims to catch patients who never present classic FAST face signs—especially women and diabetic patients—while ambulances are still routing.

NHS Greater Glasgow’s stroke directorate said minutes saved at hub intake matter more than another hospital lobby kiosk app.

Who owns the company if the raise fails

Pre-seed runway is fourteen months at current burn. If MHRA demands a full device certification, founders told investors they may need a Series A or a licensing deal with a larger diagnostics vendor. Scottish Enterprise’s grant clawback triggers if NeuroVox relocates IP outside Scotland within five years.

Founders retain board control with two seats; Eos holds one observer seat until Series A.

Regulatory and data paths

Voice recordings are special-category health data; lawful basis is substantial public interest for NHS research pilots. Samples stay in encrypted enclaves; clinicians access scores, not raw audio, on hub tablets. Caldicott approval covers 600 patients over six months.

UK GDPR’s research provisions require transparent participant information sheets read to patients or relatives during callbacks—a step call handlers worry will lengthen already stressed conversations.

Competition and clinical scepticism

Viz.ai and Brainomix sell imaging-based triage tied to hospital PACS; few UK ambulances use them pre-hospital. Vocal biomarker startups in the US raised larger rounds, but NHS procurement favours UK hosting and open NHS API patterns NeuroVox claims to follow.

Consultant neurologists privately question whether hub background noise from radios will swamp models trained on quiet booth recordings—a variable the pilot’s protocol explicitly tracks.

What paramedics will notice

If the tablet shows an amber score, hubs may request a second senior nurse listen-in; red scores trigger early stroke team paging but not bypass of on-scene clinical assessment. Union reps asked whether scores could feed performance management; NeuroVox and the ambulance service signed a joint memo saying algorithm outputs cannot be used in disciplinary cases during the pilot.

Next milestones

First hub go-live is scheduled for November at a site InfoHandle agreed not to name until families are briefed. Positive results could unlock Scottish Government innovation bridge funding referenced in May’s stroke action plan.

For Glasgow’s medtech scene, NeuroVox is a small bet on whether voice—already captured in emergency calls—can be turned into triage signal without another wearable. For investors, the question is whether a pre-seed cheque survives MHRA scrutiny long enough to become either a licensed device or acquihire fodder for a imaging triage giant. Ambulance crews will judge it by whether the tablet helps or slows the bay on a rainy Friday night.